No one is suppressing the price. No news about vaccine progress, no nothing. That's why it is still stuck at this level.

careful, that 0.265 may just be breached before session ends

It's moving up again. 0.29 will soon complete judging from the demand from 0.285. Those selling at 0.30 have pulled back somewhat, either to sell at 0.295 or holding to wait higher after 0.30

good closing - next opening will be interesting to watch

Kanger has the potential to break through 0.225. Once it does that, then it will be above its psychological resistance of 0.18-0.19 barrier. Vaccines close to being released worldwide, with Pfizer now leading, let's hope Sinopharm will announce theirs and their tests worldwide. Russia is also on the chase with Sputnik. The vaccine race to the last mile has begun. Let's see where it will spur Kanger

@
investisthekey @bowman...go check jayjay123 post..all info is there..lol

Ah, thank you. Then no wonder my charts are telling me it will test 0.29 today and if it breaks through, you will be prosperous. Let's wait and see.

@
Orlando Wah licence issued in no time

Where is your source?

Technically, 0.225 through 0.24 is good buy. If you missed 0.205 yesterday, chances are that it may not happen again. The MACD is about to cross the signal line in about one hour, meaning it should be headed to its previous highs of about 0.25-0.27 yesterday.

weekend coming soon, play it safe folks. unless you already have one foot in. otherwise just wait. The market is ruthless. You lose, you pay. Patience and research is your key. Waiting often wins.

@BearishTrend At coming third round 19cts soon

0.185 or lower is safer. Trending down now

Wait at 0.18 or 0.17, which is MA200. If it touches that, it will be oversold. Going in wont harm unless more sell-out

No one read this?

https://www.theedgemarkets.com/article/systematization-cancels-rm22-mil-acquisition-industrial-glove-maker

looks like Kanger is not moving any time in the next two weeks at least. The one thing is certain when investing - no fools will part with his money if there is not solid reason to. Frankly, for this reason, why should people push the price when there is no substantial news about what it is doing next. Sinopharm is near the end of its trials and possibly go live by next month. As its distributor here, at least Kangar can announce who he might be working with for logistical support (vaccines must be transported fast, at sub-zero). So far, nothing from Kanger board yet. Just keep calm and wait.

Macd is showing decline - if can wait, wait a little while.Can even wait at 0.19 or 0.195 looking at the volatility of trade (selldowns especially) the last 15 minutes.

shuld be able to hit 0.27 and take a rest. just got out at 0.245. to those still in, stay focussed

from left hand to right hand

By the way, AT today made up 1/5 of total traded shares in KLSE - and this is probably the first time any seen
with such a momentum

0.23 will be tested and i believe it has enough momentum to break 0.235.

If you go by KYY's reasoning, once production starts in Dec, then AT should outdo market. We are talking about nitrile gloves which is the in-thing now as compared with rubber gloves.

This is KKY's reasoning - not sure can hold water or not:

https://koonyewyin.com/2020/11/10/at-systematization-is-the-most-underrated-unknown-glove-maker/

everyone collecting at 0.185. who knows

nvestisthekey @bowman..u joking....sell down?

Nope - from 0.23 to 0.215 now. May hit 0.19 or 0.185 if this continue

selldown coming now - careful. take profit is enter early or may get held back

@xuxu up too fast, no reason can support the price so will down back. hehe

I think you are right somewhat. If you look at it, there is no fundamental change. Moratorum has been discontiued but in truth, there will be debt restructuring as well - not to mention NPLs. how are all these taken into account when investing in this bank? Or is it merely speculations since there are no major announcements

@DrHash Bowman, SinoPharm has 2 vaccine candidates...

I am not worried about how many they have. The fact that they fulfill the pretrial requisites set by WHO and with WHO monitoring makes them very likely to outperform others. But this is big money - China is prepared to go on the low to salvage its ravaged image from Wuhan. But for countries like US, France and Germany - would they want the same especially their economy had been battered by the lack of action, or plain ignorance of science

Read in between the lines. This came after Pfizer claimed that its vaccine is above 90% effective. And you have a story which is non-conclusive by Bloomberg, all based on possible circumstantial sources that are probably unrelated. Coronavac has been tested in China by the hundreds of thousands and the probably of even one death would have caused concern. One would imagine if Coronavac and those under Sinopharm are found to be above 95% effective, what would that news do to Pfizer and related stocks operating outside China. Also, China did say that their effective vaccine would be a service to the world - meaning they could make them cheap for all to access. My take is that the Chinese vaccines are very near completion and release, including the one Kanger will distribute. But let's wait and see

Cheapest banking stock for speculative play. Someone said Qr results not in yet. Very true. How much liabilities accrued because of extended moratorium previously, NPLs, and the likes are not known yet.

Started already. Look at Sinopharm stock these two days.

9.3% risk for minimum 6% gain?

get ready - this week could be another interesting one for Kanger. Look at the previous seven trading days.

I think this is looking positive - it has been stopped at 1.20plus but I believe it will break through in these coming days to reach new heights. For one, the world is buoyant of the Biden win - it means US will lead the way with emphasis on medical and healthcare to fight Covid scourge. China is already almost winning. The focus is now on US, and if my guess is right, the renewed focus on US will means healthcare stocks - gloves, medical equipment, software, logistics related - will be receiving some of the positive aftershocks.

As to why the directors are selling, well, if you have bought cheap and did not lock in the earlier round, what's wrong with them selling now? Dont forget, the selling by directors was made before the US elections.

Go read up about the budget here https://www.freemalaysiatoday.com/category/nation/2020/11/06/live-high...


Digital transformation

*RM1 billion for Industrial Digital Transformation Scheme
*RM150 million in grants for the digitalisation and automisation of small- and medium-sized enterprises (SMEs)

Appasia will benefit from this probably, with the development of e-Confirm and roll-out. Banks and audit firms will likely to be encouraged to transform their current system to this and similar systems. Not forgetting, its current project with TM to establish that e-marketplace digital platform using the Yellow Pages.

Budget 2021: RM1 billion for Industrial Digital Transformation Scheme. Network security will benefit as do transitional gateways. Does Systech have either in this sector anyone knows?

@Primeinvestor jcy - results rm80m rumour

Okay, it has turned - looks like more buyers are supporting it. Probably head back towards 0.76 thereabouts

Monitor Sinopharm stock also - it is on the rise as December nears when it says it will get the vaccine ready. Unlike Bintai's partner Generex whose shares have taken a beating

@NPRA1985 I'll say this again. If anyone wants to enter better enter now. Dont regret once if flies.

I think it has entered its momentum phase - now trading above 20MA should take it towards next resistance at 0.255

For one lot of Bintai (whose vaccine progress is not known), you can buy 4 lots of Kanger (which Sinopharm is in its final stages of trial).

0.19 is a good EP because that would have given it enough momentum to scale new heights - with next resistance level at 0.255

Looks like it is moving slowly like Bintai Kinden in the early days of 0.28 and below. Then it just flew from Aug 13 onwards. The difference is that Sinopharm is almost done trial-testing while Bintai is still groping for a vaccine. This looks like it

Good for Kanger - looks like this is the one vaccine-related counter to move now

Not surprising if it closes back to 0.675 judging from the selling points from 0.70

You buy one rumours? That is one way of going to hell.

@JXnotJAX bow that's first value, 2nd value @ 1.18?
28/10/2020 2:29 PM

i don't buy for immediate gains. Whether it is 0.80 or 1.18 don't matter. Long term investment until fundamental prove otherwise.

Vsolar is being played by the big boys. If you don't have at least 100k units, just leave it there until Kingdom Come. If it rises, it rises. Otherwise there is no reason why people should push the stock to new levels of high. As it is, there is no substantial news for this company. Previously, at least the share base is not so huge. Now, it will take days to mop up panic selling. Even if there is good economic data, at most, it will go up to another 5 sen. Not more, very likely

Recent developments in Sabah and elsewhere is driving demand for increased bed capacity and other medical peripherals LKL is producing. Might one guess that the coming quarter will be a profitable one also, given spending have been relegated to the last.

This below will also factor into the anticipated profitability as it is supplying nitrile gloves as well

http://lkl.irplc.com/medianews.htm?filepath=LKL/LKL-TheEdgeMarkets-14092020.pdf

The downtrend is ending from the looks of the direction it is taking on the charts.

@Asyraf96 Buy bintai nows for pullback


What pullback. Look at Generex share prices and see if it is going anywhere

Locked in retailers are selling off. Look at volume, if small, then it is only these selling out because of several reasons - lack of funds, margin calls, or simply unsure of their investment. Right now, volume is only 2mil. At RM1.02, it is steal

Interesting:
https://codeblue.galencentre.org/2020/10/05/fitch-raises-political-ties-in-covid-vaccine-deals-including-malaysian-bamboo-company/


"Sinopharm had initiated their Phase Three clinical trial for the Covid-19 vaccine on July 17, which puts it on a similar timeline to candidates in development from Moderna and Pfizer, which both entered their Phase Three studies on July 27.

Sinopharm chairman Liu Jingzhen reportedly said in August that he expects Sinopharm’s vaccine to be in the market by December 2020.

According to Fitch Solutions, data from Phase One/Two trials of Sinopharm’s coronavirus candidate vaccine showed that it was able to stimulate a robust immune system with only limited safety concerns. Adverse effects seen were low-grade symptoms, such as fever and pain at the injection site, with no other serious adverse effects."

Just be careful with hardearned money. Time like this is not for gambling - check until you are confident with the findings, then invest. A single stock trader is no match for funds that work in tandem. Has Pos fundamentals improved since last year? Results matter. Check, check and check.

Look at KWAP disposal since July will tell you lots

https://malaysiastock.biz/Company-Announcement.aspx?id=1263742